» Articles » PMID: 38493228

The Italian Registry of Families at Risk for Pancreatic Cancer (IRFARPC): Implementation and Evolution of a National Program for Pancreatic Cancer Surveillance in High-risk Individuals

Overview
Journal Fam Cancer
Publisher Springer
Specialty Oncology
Date 2024 Mar 17
PMID 38493228
Authors
Affiliations
Soon will be listed here.
Abstract

Screening programs for early detection and treatment of pancreatic cancer (PC) and its precursor lesions are increasingly implemented worldwide to reduce disease-specific lethality. Given the relatively low prevalence of the disease, the ideal target of such approaches is an enriched cohort of individuals harboring a lifetime risk of developing PC significantly higher compared to the general population, given either a substantial aggregation of PC cases in their family (i.e. familial pancreatic cancer) or a genomic landscape enriched with pathogenic variants associated with pancreatic carcinogenesis (i.e. mutation carriers). In Italy, a national registry for the census and surveillance of high-risk individuals for PC was launched in 2015, enrolling some 1200 subjects as of today. In this perspective, the scientific background, multi-level structure, and evolution of IRFARPC are outlined, as well as its long-term results, future developments, and areas for improvement.

Citing Articles

Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue.

Vasen H, Canto M, Goggins M Fam Cancer. 2024; 23(3):209-215.

PMID: 38844715 PMC: 11255030. DOI: 10.1007/s10689-024-00404-0.

References
1.
Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

2.
Blackford A, Canto M, Klein A, Hruban R, Goggins M . Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst. 2020; 112(11):1162-1169. PMC: 7669234. DOI: 10.1093/jnci/djaa004. View

3.
Overbeek K, Levink I, Koopmann B, Harinck F, Konings I, Ausems M . Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2021; 71(6):1152-1160. PMC: 9120399. DOI: 10.1136/gutjnl-2020-323611. View

4.
Shah I, Silva-Santisteban A, Germansky K, Trindade A, Raphael K, Kushnir V . Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes From a Prospective Multicenter Study. Am J Gastroenterol. 2023; 118(9):1664-1670. DOI: 10.14309/ajg.0000000000002314. View

5.
Dbouk M, Katona B, Brand R, Chak A, Syngal S, Farrell J . The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. J Clin Oncol. 2022; 40(28):3257-3266. PMC: 9553376. DOI: 10.1200/JCO.22.00298. View